Research Support

NovaDerm® is classified as a Humanitarian Use Device (Orphan biologic/drug), which provides a more rapid regulatory pathway to approval and commercialization.

Regenicin will continue to seek support from the following Governmental and Non Governmental sources:

Governmental Support:

• National Institutes of Health (NIH): The NIH funds research in skin tissue engineering and regenerative medicine.

• Department of Defense (DoD): The DoD supports research to improve treatments for military personnel with burn injuries. The Military Burn Research Program (MBRP) provides funding opportunities, such as the Technology/Therapeutic Development Award, to develop new treatments for burn injuries.

• Biomedical Advanced Research and Development Authority (BARDA): BARDA collaborates with organizations to develop and commercialize skin regeneration therapies. For example, BARDA has partnered with Avita Medical to support the development and procurement of the ReCell device, which enables clinicians to treat wounds using a patient’s own cells.

Non-Governmental Organization Support:

• Canadian Institutes of Health Research (CIHR): CIHR funds research in skin tissue engineering, as seen in studies advancing treatments for burn patients.

• Ontario Institute of Regenerative Medicine (OIRM): OIRM supports regenerative medicine research, including projects focused on skin regeneration for burn victims.

These organizations play crucial roles in advancing research and development of skin replacement therapies, aiming to improve outcomes and quality of life for burn victims.